Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recent developments in bisphosphonate therapy.

Stuart L Silverman1, Michael Maricic

  • 1UCLA/Cedars-Sinai, Osteoporosis Medical Center, Beverly Hills, California 90211, USA. stuarts@omcresearch.org

Seminars in Arthritis and Rheumatism
|February 17, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cost-Effectiveness of Opportunistic Osteoporosis Screening Using Chest Radiographs With Deep Learning in the United States.

Journal of the American College of Radiology : JACR·2025
Same author

Cost-effectiveness of radiofrequency echographic multi-spectrometry for the diagnosis of osteoporosis in the United States.

JBMR plus·2024
Same author

Clinical and demographic factors determining patient fracture risk decision point (FRDP): The improving risk communication in osteoporosis (RICO) project.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2024
Same author

Efficacy and safety of candidate biosimilar CT-P41 versus reference denosumab: a double-blind, randomized, active-controlled, Phase 3 trial in postmenopausal women with osteoporosis.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2024
Same author

Race-specific FRAX models are evidence-based and support equitable care: a response to the ASBMR Task Force report on Clinical Algorithms for Fracture Risk.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2024
Same author

Comparison of the cost-effectiveness of sequential treatment with abaloparatide in US men and women at very high risk of fractures.

Aging clinical and experimental research·2024
Same journal

Autoantibody associations in patients with early diffuse cutaneous systemic sclerosis: the prospective registry of early systemic sclerosis.

Seminars in arthritis and rheumatism·2026
Same journal

Effectiveness and safety of primary thromboprophylaxis in antiphospholipid antibody carriers by serological 2023 ACR/EULAR domains.

Seminars in arthritis and rheumatism·2026
Same journal

Clustering-based stratification of fibromyalgia subtypes: A comparative analysis of medicated and non-medicated cohorts from two academic centers.

Seminars in arthritis and rheumatism·2026
Same journal

Imaging techniques for assessing the hand in systemic sclerosis: a systematic review.

Seminars in arthritis and rheumatism·2026
Same journal

Evaluating unsupervised and rule-based phenotyping methods versus administrative code counts for systemic sclerosis identification.

Seminars in arthritis and rheumatism·2026
Same journal

Associations between MRI features and pain in first metatarsophalangeal joint osteoarthritis.

Seminars in arthritis and rheumatism·2026
See all related articles

Newer nitrogen-containing bisphosphonates effectively treat osteoporosis, increasing bone density and reducing fracture risk. Improved formulations offer flexible oral or intravenous options with a safety profile similar to placebo.

Area of Science:

  • Rheumatology
  • Pharmacology
  • Bone Metabolism

Background:

  • Osteoporosis, a condition characterized by reduced bone density, affects millions, particularly postmenopausal and glucocorticoid-induced cases.
  • Bisphosphonates are a cornerstone therapy for osteoporosis, with ongoing advancements in their development and application.

Purpose of the Study:

  • To review current developments in nitrogen-containing bisphosphonates for rheumatologic conditions.
  • To examine the efficacy, safety, and administration of new bisphosphonate formulations for osteoporosis.

Main Methods:

  • Review of pathology, diagnosis, and treatment of postmenopausal and glucocorticoid-induced osteoporosis.
  • Analysis of clinical trial data for oral and intravenous nitrogen-containing bisphosphonates.

Related Experiment Videos

  • Discussion of adverse events and strategies to improve patient adherence.

    • Main Results:

    • Oral bisphosphonates demonstrate efficacy in increasing bone mineral density and reducing fracture risk.
    • Newer bisphosphonate formulations show a safety profile comparable to placebo, with manageable gastrointestinal side effects.
    • Flexible dosing frequencies and administration routes (oral/intravenous) are available.

    Conclusions:

    • Nitrogen-containing bisphosphonates represent crucial therapeutic agents for osteoporosis prevention and treatment.
    • Advancements in bisphosphonate therapy offer improved patient options and adherence potential.